Clinical trials in systemic lupus erythematosus: a status report on ongoing trials

Yildirim-Toruner C, Diamond B (2011) Current and novel therapeutics in treatment of SLE. J Allergy Clin Immunol 127(2):303–314. doi: 10.1016/j.jaci.2010.12.1087

Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC (2010) Pathogenesis of human systemic lupus erythematous: recent advances. Trends Mol Med 16(2):47–57. doi: 10.1016/j.molmed.2009.12.005

Bongu A, Chang E, Ramsey-Goldman R (2002) Can morbidity and mortality of SLE be improved? Best Pract Res Clin Rheumatol 16(2):313–332. doi: 10.1053/berh.2001.0228

Paul JR, Ranganathan P (2011) Clinical trials in rheumatoid arthritis: a status report from the Clinical Trials.gov website. Rheumatol Int 32:1831–1835. doi: 10.1007/s00296-011-2027-3

Gillen JE, Tse T, Ide NC, McCray AT (2004) Design, implementation and management of a web-based data entry system for ClinicalTrials.gov. Stud Health Technol Inform 107:1466–1470. doi: 10.3233/978-1-60750-949-3-1466

DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S et al (2004) International committee of medical journal editors. Clinical trial registration: a statement from the international committee of medical journal editors. JAMA 292:1363–1364. doi: 10.1056/NEJMe048225

Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 63(8):834–840. doi: 10.1016/j.jclinepi.2010.02.005

Lewis JA, Jonsson B, Kreutz G, Sampaio C, Zwieten-Boot VB (2002) Placebo controlled trials and the declaration of Helsinki. Lancet 359(9314):1137–1140. doi: 10.1016/S0140-6736(02)08277-6

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA et al (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61(9):1168–1178. doi: 10.1002/art.24699

Runkel L, Stacey J (2014) Lupus clinical development: will belimumab’s approval catalyse a new paradigm for SLE drug development? Expert Opin Biol Ther 14(4):491–501. doi: 10.1517/14712598.2014.884065

Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167–1170. doi: 10.1136/bmj.326.7400.1167

Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C et al (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289:1107–1116. doi: 10.1001/jama.289.9.1107

Dall’Era M, Wofsy D (2006) Clinical trial design in systemic lupus erythematous. Curr Opin Rheumatol 18:476–480. doi: 10.1097/01.bor.0000240357.22680.63

Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P (2000) Endpoints: consensus recommendations from OMERACT IV. Lupus 9(5):322–327

Thanou A, Merrill JT (2014) Treatment of systemic lupus erythematous: new therapeutic avenues and blind alleys. Nat Rev Rheumatol 10(1):23–24. doi: 10.1038/nrrheum.2013.145

Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, Brink R et al (2003) BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 112(2):286–297. doi: 10.1172/JCI18025

Haubitz M (2010) New and emerging treatment approaches to lupus. Biologics 4:263–271. doi: 10.2147/BTT.S7581

Abu-Shakra M, Buskila D (2002) Update on the treatment of systemic lupus erythematous: therapeutic highlights from the sixth international lupus conference. Isr Med Assoc J 4(1):71–73

Anolik J (2005) New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 19(5):859–878. doi: 10.1016/j.berh.2005.05.006

Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100(5):2610–2615. doi: 10.1073/pnas.0337679100

Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, Verda L et al (2006) Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematous. JAMA 295(5):527–535. doi: 10.1001/jama.295.5.527

Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A (2012) Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA 307(17):1838–1847. doi: 10.1001/jama.2012.3424